NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
Clinical Trials
7 trialsNCT06224673 2026-02-13
ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
University of California, San Francisco
Phase 2 Not yet recruiting
NCT05426486 2024-10-30
A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
Shengjing Hospital
Phase 2/3 Active not recruiting
NCT06578286 2024-08-29
ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd
Fudan University
Phase 2 Not yet recruiting
NCT04983121 2022-09-13
Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients
Shengjing Hospital
Phase 2 Recruiting
NCT05018702 2022-06-01
ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases
Fudan University
Phase 2 Unknown
NCT05018676 2022-04-25
ARX788 in Breast Cancer With Low Expression of HER2
Fudan University
Phase 2 Unknown